Alnylam Pharmaceuticals has unveiled its five-year strategic growth plan, dubbed "Alnylam 2030," despite recently reporting that quarterly sales of its key drug slightly underperformed investor expectations. Greenstreet stated that the company has established a sustainable innovation engine coupled with a high-performing commercial organization, which has been instrumental in driving its growth.
Alnylam 2030 Plan Objectives
CEO Yvonne Greenstreet outlined the following targets for the next five years:
- Establish a leading market position in the disease area treated by its top-selling drug, Amvuttra.
- Introduce two new medicines for different diseases, each with the potential to generate over one billion dollars in annual sales.
- Invest 30% of its sales into research and development.
- Achieve an annual sales growth of 25%.
- Maintain a 30% operating margin, excluding one-time costs and other adjustments.